通化东宝与科兴制药达成出海合作以来，双方发挥各自优势，高效协同，积极推进利拉鲁肽注射液海外 注册、GMP审计等工作。2025年4月，产品获得哥伦比亚GMP证书；2025年11月，产品在秘鲁获批上 市。此次，该产品再获巴西GMP证书，通化东宝产品已在拉美市场形成多点突破的良好格局，国际化 步伐持续提速。 拉美等新兴市场糖尿病患病率高、患者数量增长迅速，对高品质、高可及性的生物药需求日益迫切。在 此背景下，通化东宝利拉鲁肽注射液产品将为当地患者提供更丰富的治疗选择。 中证报中证网讯(记者宋维东)日前，通化东宝（600867）与合作伙伴科兴制药携手的出海产品利拉鲁肽 注射液获得巴西国家卫生监督局(ANVISA)颁发的药品生产质量管理规范(GMP)证书。此举标志着通化 东宝利拉鲁肽注射液在拉美核心市场的合规化进程迈入新阶段，为产品登陆巴西市场筑牢核心资质基 础，这也是公司GLP-1类产品国际化布局的又一重要进展。 作为全球医药领域公认的高标准药品质量管理体系，PIC/S成员国的GMP认证以严苛、规范、互认度高 著称。巴西作为拉美地区核心的医药市场与PIC/S(国际药品认证合作组织)重要成员国，ANVISA监管体 系与 ...

Core Viewpoint - The approval of the ANDA for Methylene Blue Injection by the FDA marks a significant milestone for the company, enhancing its international product pipeline and supporting its globalization strategy [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Chengdu ShuoDe Pharmaceutical Co., Ltd., received notification from the FDA regarding the approval of the ANDA for Methylene Blue Injection [1] - The active ingredient of Methylene Blue Injection is Methylene Blue, indicated for the treatment of acquired methemoglobinemia in children and adults [1] Group 2: Product Commercialization - Methylene Blue Injection is the company's third formulation to enter the international market, with the raw material also registered with the FDA [1] - The company has signed an exclusive supply and distribution agreement with an international pharmaceutical company for the commercialization of Methylene Blue Injection in the U.S. [1] - Under the agreement, the international company will be responsible for the comprehensive commercialization operations in the U.S., while the company will focus on production and supply, receiving milestone payments, sales revenue, and a share of the sales profits [1]

Core Viewpoint - The company has received approval from the U.S. FDA for its injectable bortezomib abbreviated new drug application (ANDA), indicating that the product is bioequivalent and therapeutically equivalent to the original drug, which enhances the company's international market presence and product pipeline [1][4]. Drug Basic Information - Drug Name: Injectable Bortezomib - Dosage Form: Injection - Specification: 3.5 mg - Approved Indications: - Treatment of multiple myeloma patients who have not received prior treatment and are not suitable for high-dose chemotherapy, in combination with melphalan and prednisone [1]. - Part of a combination therapy for multiple myeloma patients under 65 years old who have not received prior treatment, used for high-dose chemotherapy with autologous stem cell rescue following induction therapy [1]. - Treatment of multiple myeloma patients who have received at least one prior treatment and whose disease has progressed [2]. - Treatment of adult patients with mantle cell lymphoma who have not received prior treatment, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone [2]. Other Drug-Related Information - In April 2024, the product received a drug registration certificate from the National Medical Products Administration of China, indicating it passed the consistency evaluation [3]. - In October 2025, the product obtained marketing authorization from the Australian Therapeutic Goods Administration (TGA) [3]. Impact on the Company - The approval of the injectable bortezomib ANDA by the U.S. FDA signifies that the company's research and production meet original drug standards, showcasing its international research and production capabilities [4]. - This approval enriches the company's international sales product pipeline and advances its internationalization strategy, positively impacting the company's product influence and future operating performance [4]. - The approval grants the drug legal sales rights in the U.S., enhancing the company's market competitiveness and providing a new profit growth point for sustainable development [4].

Core Viewpoint - Hainan Shuangcheng Pharmaceutical Co., Ltd. has received FDA approval for its injectable Bortezomib ANDA, marking a significant milestone in its international expansion and product portfolio enhancement [1] Group 1: Company Performance - As of December 18, 2025, *ST Shuangcheng (002693) closed at 6.58 yuan, down 0.3% from the previous trading day, with a total market capitalization of 2.729 billion yuan [1] - The stock opened at 6.59 yuan, reached a high of 6.79 yuan, and a low of 6.55 yuan, with a trading volume of 32.0879 million yuan and a turnover rate of 1.17% [1] Group 2: Regulatory Approvals - The injectable Bortezomib ANDA has been recognized by the FDA as being bioequivalent and therapeutically equivalent to the reference drug [1] - The product has also received approval from the National Medical Products Administration of China and has passed the consistency evaluation, along with obtaining listing permission from Australia's TGA [1] Group 3: Strategic Implications - The FDA approval signifies that the company's product meets international standards, which is expected to enhance its international influence and operational performance [1] - This development will enrich the company's international sales product line and advance its globalization strategy [1] - The announcement also notes that overseas sales may be affected by regulations, policies, market conditions, and exchange rate fluctuations [1]

Core Viewpoint - Chengdu Yuandong Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Chengdu ShuoDe Pharmaceutical Co., Ltd., successfully passed the FDA's pre-approval inspections for its Naloxone nasal spray product with zero deficiencies [1][2]. Group 1: Inspection Details - The FDA inspections took place from May 6 to 9 and May 16 to 22, 2025, focusing on current Good Manufacturing Practices (cGMP) and BioResearch Monitoring (BIMO) [1]. - The inspections were conducted for the Naloxone nasal spray product, specifically on the nasal spray production line [1]. - The inspection concluded with a zero deficiency report (no 483), indicating compliance with FDA standards [1]. Group 2: Product and Company Impact - This inspection marks the second time ShuoDe Pharmaceutical has undergone an FDA inspection and the first for its nasal spray production line [1]. - The successful inspection is expected to expedite the approval process for the company's submitted Abbreviated New Drug Applications (ANDA) in the U.S. and support the implementation of its internationalization strategy [1].

Group 1 - The company’s subsidiary, Tianjin Pharmaceutical Co., Ltd., has received a registration certificate from the Ministry of Health of the Republic of Panama for its injectable drug, Methylprednisolone Sodium Succinate, allowing it to produce and sell the product in the Panamanian market [1][2] - The drug is a corticosteroid used for anti-inflammatory treatment, immunosuppressive therapy, treatment of blood diseases and tumors, and shock treatment [1] - The global market sales for Methylprednisolone injectable products were reported to be $526 million in 2023 and $521 million in 2024 according to the IQVIA database [1] Group 2 - The registration of the drug is expected to create new opportunities for the company’s formulation business in the Panamanian market and further promote its international strategic layout [2] - The timeline for the drug's sales in foreign markets, market size, and subsequent expansion progress remains uncertain, influenced by external market conditions and exchange rate fluctuations [2]

Core Viewpoint - Ganli Pharmaceutical's insulin product has received a positive opinion from the European Medicines Agency (EMA), marking a significant step for Chinese biopharmaceuticals in the international market [1] Group 1: Company Developments - Ganli Pharmaceutical's insulin injection, Lantus® SoloStar® biosimilar, is recommended for approval by the EMA for treating diabetes in adults, adolescents, and children aged 2 and above [1] - This is the first time a Chinese-developed insulin has received positive recognition from a European regulatory body, indicating a major milestone for the company's internationalization strategy [1] - The positive opinion from the EMA is seen as a "golden passport" for entering international markets, enhancing the company's credibility and paving the way for future product launches in Europe [1][2] Group 2: Market Context - The European diabetes patient population aged 20 to 79 has surpassed 65.6 million, with related medical expenditures nearing $200 billion, highlighting a strong demand for effective and cost-efficient treatment options [2] - Currently, the European insulin market is dominated by Sanofi, with projected sales of €819 million in 2024, indicating a significant opportunity for Ganli Pharmaceutical to alter the market landscape [2] Group 3: Financial Performance - In the first three quarters of 2025, Ganli Pharmaceutical reported domestic formulation revenue of 2.624 billion yuan, a year-on-year increase of 45.6%, reflecting a robust recovery in the domestic market [2] - The company's international business also showed strong performance, with overseas sales revenue reaching 353 million yuan, up 45.5% year-on-year, indicating a growing order scale [2] - The company has achieved a 32.6% growth rate in agreement volume for six insulin products in the upcoming national procurement in 2024, laying a solid foundation for performance recovery [2]

Core Viewpoint - The company is actively promoting its innovative drug, Anladiwei, for the treatment of influenza, with positive clinical trial results and plans for international market expansion [2][4]. Financial Performance - As of October 24, 2025, the company's stock closed at 17.96 yuan, down 2.55%, with a turnover rate of 5.9%, trading volume of 449,200 shares, and a transaction amount of 811 million yuan [1]. Product Development - Anladiwei is the world's first targeted drug for the PB2 subunit of the influenza A virus, showing rapid and effective treatment capabilities with low resistance [2]. - The drug has completed Phase III clinical trials, demonstrating significant efficacy against various influenza virus strains, including H1 and H3 subtypes [4]. Market Strategy - The company has established a commercialization partnership for Anladiwei in Macau and is exploring further international market opportunities [3][4]. - The company is monitoring disease dynamics and is prepared to enhance production and sales efforts [4]. Investor Engagement - The company has clarified that there are no current financing plans and emphasized adherence to disclosure obligations [2]. - The company is open to suggestions regarding marketing strategies to increase awareness of Anladiwei's efficacy [2]. Market Activity - On October 24, there was a net outflow of 132 million yuan from major funds, while retail investors saw a net inflow of 14 million yuan [5].

Core Viewpoint - The company is focusing on international market opportunities for its pharmaceuticals, specifically through a collaboration with Sinovac Biotech for the commercialization of Anglatavir tablets in Macau, which aims to enhance its brand presence overseas and support its international expansion efforts [1] Group 1 - The company has established a commercial partnership with Sinovac Biotech for Anglatavir tablets in Macau [1] - This collaboration is intended to create a brand radiating effect in international markets [1] - The company plans to explore further international market opportunities and accelerate its globalization efforts [1] Group 2 - The company is closely monitoring disease dynamics and is committed to effective drug production and sales [1]

Core Viewpoint - Tonghua Dongbao has received the drug registration certificate for insulin aspart injection from the Indonesian Food and Drug Authority, allowing the company to sell this product in Indonesia, which enhances its international market presence and competitiveness [1] Group 1: Product Information - Insulin aspart injection is a rapid-acting insulin analog that takes effect within 10-20 minutes after subcutaneous injection and lasts for 3-5 hours, primarily used to control postprandial blood sugar [1] - Insulin aspart is typically administered immediately before meals and can also be given right after meals if necessary, often in combination with long-acting insulin for comprehensive blood sugar management [1] Group 2: Strategic Implications - The approval of insulin aspart injection by the Indonesian authority signifies that Tonghua Dongbao is now permitted to market this product in Indonesia, which is beneficial for expanding the company's international product line [1] - This development is expected to enhance the company's brand image, facilitate the expansion of international business, accelerate its presence in emerging markets, and improve its competitiveness in the global market [1]